Long-acting (LA) injectable cabotegravir (CAB) and rilpivirine (RPV) is a well-established and tolerated option for antiretroviral treatment (ART) in eligible people with HIV (PWH). This study aims to describe adverse events (AEs) reported in a multicentric, prospective cohort, assessing their severity and the timing of occurrence. Additionally, it explores the characteristics of PWH who experienced these reactions.
SC28 Adverse event development in people with HIV on long-acting Cabotegravir + rilpivirine: timing and clinical insights
Pellicano', G F;
2025-01-01
Abstract
Long-acting (LA) injectable cabotegravir (CAB) and rilpivirine (RPV) is a well-established and tolerated option for antiretroviral treatment (ART) in eligible people with HIV (PWH). This study aims to describe adverse events (AEs) reported in a multicentric, prospective cohort, assessing their severity and the timing of occurrence. Additionally, it explores the characteristics of PWH who experienced these reactions.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
